Navigation Links
TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution
Date:5/29/2009

LA JOLLA, Calif., May 29 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that its Board of Directors has determined, after consideration of potential strategic and financing alternatives, that it is in the best interests of the Company and its stockholders to liquidate the Company's assets and to dissolve the Company. The Company's Board of Directors has unanimously approved a Plan of Liquidation and Dissolution of the Company (the "Plan of Dissolution") subject to stockholder approval. The Company intends to hold a special meeting of the stockholders to seek approval of the Plan of Dissolution and today it filed related proxy materials with the Securities and Exchange Commission (the "SEC").

Although the Board of Directors has approved the Plan of Dissolution, the Company continues to seek and will consider any reasonable alternative strategic or financing proposals presented to the Company. The investment firm Merriman Curhan Ford remains engaged as the Company's financial advisor to assist in the evaluation of strategic options, including the possible sale of the Company or its AMPA/kainite receptor antagonist product candidates.

The Plan of Dissolution contemplates an orderly wind down of the Company's business and operations. If the Company's stockholders approve the Plan of Dissolution, the Company intends to file a certificate of dissolution, satisfy or resolve its remaining liabilities and obligations, including any contingent liabilities and costs associated with the liquidation and dissolution and make reasonable provisions for unknown or unresolved claims and liabilities, if any. Following stockholder approval of the Plan of Dissolution and the filing of the certificate of dissolution, the Company plans to delist its common stock from the Nasdaq Global Market.

IMPORTANT A
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... even the entire body to visualize long-range connections between ... a long-time dream of biologists. A study published by ... Cell has now made that dream a ... and human tissue biopsies transparent, while keeping the cellular ... way for a better understanding of brain-body interactions, more ...
(Date:7/31/2014)... July 31, 2014 Rogne Bioscience, a privately-held ... Area , has acquired a licence to anti-inflammatory ... company. The potent anti-inflammatory activity of the peptides was ... University of Oxford,s Sir William Dunn School ... raised over $1.5 million in seed financing, is developing ...
(Date:7/31/2014)... 2014 CollabRx, Inc. (NASDAQ: CLRX), a ... in oncology, today announced that it will hold an ... the Company's financial results for the first quarter of ... business in the current fiscal year. , The dial-in ... August 14, 2014, at 5 p.m. EDT (2 p.m. ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... today the integration of Omicsoft’s Array Suite with ... platforms will be able to send data in tranSMART ... works with all versions of tranSMART including the new ... art statistics, visualization and storage for the analysis of ...
Breaking Biology Technology:See-through organs and bodies will accelerate biomedical discoveries 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3
... Thursday, November 5, 2009 at 4:30 p.m. Eastern Time ... OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: ... third quarter and nine months ended September 30, 2009 ... of 2009. , The following consolidated results reflect the ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... financial results for the third quarter ended September 30, ... September of this year, the FDA,s Arthritis Advisory Committee ... of XIAFLEX(TM) for the treatment of Dupuytren,s disease, and ...
... Texas, Nov. 5 Wound Management Technologies, Inc., (WNDM), announced ... to purchase all healthcare-related assets of Virtual Health Technologies, Inc. ... be paid $1,000,000 in cash and debt, 4,000,000 shares of ... on the Veriscrip technology being acquired from VHGI. ...
Cached Biology Technology:OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3
(Date:7/31/2014)... genes to the earliest common ancestor of butterflies ... an extensive "Tree of Lepidoptera" in the first ... , Among the study,s more surprising findings: Butterflies ... to large ones, which completely changes scientists, understanding ... that some insects once classified as moths are ...
(Date:7/31/2014)... It has long been known that biomass burning ... savannah as a ritual , slash-and-burn agriculture and ... public health. , But until the release of ... Environmental Engineering Professor Mark Z. Jacobson, the degree ... , Jacobson,s research, detailed in a paper published ...
(Date:7/31/2014)... (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity ... (HPV) vaccine Cervarix. Women vaccinated with the ... than nine years, and vaccine efficacy (VE) ... the longest follow-up report for a licensed ... the full paper. , HPV and ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... A tale of two sisters has helped researchers solve ... causes an inherited form of the lung disease Pulmonary Alveolar ... Journal of Experimental Medicine , a research team led ... possibility of an inhaled therapy to overcome a chain of ...
... at the Johns Hopkins Bloomberg School of Public ... for potential human exposure to antibiotic-resistant bacteria from ... chickens from farm to slaughterhouse. A study by ... bacteria, both susceptible and drug-resistant, on surfaces and ...
... exercise seems to reduce anger expression in overweight but ... study on the topic looked at 208 typically sedentary ... afterschool aerobic exercise program or maintained their usual inactive ... common anger expressions such as slamming doors and hitting, ...
Cached Biology News:Inherited genetic cause, possible treatment found for complex lung disorder 2Inherited genetic cause, possible treatment found for complex lung disorder 3Transporting broiler chickens could spread antibiotic-resistant organisms 2Exercise helps overweight children reduce anger expression 2
...
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
... Experion software, PC, is used ... the data obtained from the Experion ... data in electropherogram and simulated gel ... other calculations in a Results table. ...
Biology Products: